Century Therapeutics, Inc. (IPSC)
After hours:
| Previous Close | 3.0000 |
| Open | 2.9800 |
| Bid | 2.9600 x 100 |
| Ask | 3.0700 x 100 |
| Day's Range | 2.9800 - 3.2000 |
| 52 Week Range | 1.2800 - 5.5100 |
| Volume | |
| Avg. Volume | 202,036 |
| Market Cap | 251.028M |
| Beta (5Y Monthly) | 1.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.83 |
GlobeNewswireCentury Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows: Fireside Chat o
- GlobeNewswire
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026 Acquisition of Clade Therapeutics strengthens Century’s position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and n
- GlobeNewswire
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024. The posters highlight the Company’s end-to-end capabilities in iPSC reprogramming and differentiation, gene
